Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin's lymphoma: an in vitro and in vivo study.
ZCL-082, a boron-containing compound, induces apoptosis of non-Hodgkin's lymphoma via targeting p90 ribosomal S6 kinase 1/NF-κB signaling pathway.
Isolation and characterization of anti-inflammatory and anti-proliferative compound, for B-cell Non-Hodgkin lymphoma, from Nyctanthes arbor-tristis Linn.
Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review.
Yasuda H, Yasuda M, Komatsu N.
Cancer Sci. 2021 Jul;112(7):2607-2624. doi: 10.1111/cas.14933. Epub 2021 Jun 11.
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Coindre JM, Blakemore SJ, Clawson A, Suttle B, McDonald AA, Woodruff M, Ribich S, Hedrick E, Keilhack H, Thomson B, Owa T, Copeland RA, Ho PTC, Ribrag V.
Lancet Oncol. 2018 May;19(5):649-659. doi: 10.1016/S1470-2045(18)30145-1. Epub 2018 Apr 9.
Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors.
Trkulja KL, Manji F, Kuruvilla J, Laister RC.
Biomolecules. 2023 Jan 5;13(1):111. doi: 10.3390/biom13010111.
The association between non-Hodgkin lymphoma and organophosphate pesticides exposure: A meta-analysis.
Hu L, Luo D, Zhou T, Tao Y, Feng J, Mei S.
Environ Pollut. 2017 Dec;231(Pt 1):319-328. doi: 10.1016/j.envpol.2017.08.028. Epub 2017 Aug 12.
Non-Hodgkin's lymphoma involving the liver: clinical and therapeutic considerations.
Salmon JS, Thompson MA, Arildsen RC, Greer JP.
Clin Lymphoma Myeloma. 2006 Jan;6(4):273-80. doi: 10.3816/clm.2006.n.001.
Bendamustine.
Balfour JA, Goa KL.
Drugs. 2001;61(5):631-8; discussion 639-40. doi: 10.2165/00003495-200161050-00009.
Treatment of non-Hodgkin lymphoma.
Hauke RJ, Armitage JO.
Curr Opin Oncol. 2000 Sep;12(5):412-8. doi: 10.1097/00001622-200009000-00005.
Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.
Herbaux C, Bachy E, Bouabdallah R, Guidez S, Casasnovas O, Feugier P, Damaj G, Tilly H, Ysebaert L, Le Gouill S, Morineau N, Gyan E, Gressin R, Houot R, Cheminant M, Morschhauser F, Thieblemont C, Haioun C, Nicolas-Virelizier E, Fornecker LM, Daguindau N, Cartron G.
Br J Haematol. 2025 Jul;207(1):110-122. doi: 10.1111/bjh.20109. Epub 2025 Apr 26.
Isolation and characterization of anti-inflammatory and anti-proliferative compound, for B-cell Non-Hodgkin lymphoma, from Nyctanthes arbor-tristis Linn.
Sana T, Qayyum S, Jabeen A, Siddiqui BS, Begum S, Siddiqui RA, Hadda TB.
J Ethnopharmacol. 2022 Jul 15;293:115267. doi: 10.1016/j.jep.2022.115267. Epub 2022 Apr 7.
Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study.
Izutsu K, Ando K, Nishikori M, Shibayama H, Goto H, Kuroda J, Kato K, Imaizumi Y, Nosaka K, Sakai R, Abe M, Hojo S, Nakanishi T, Rai S.
Int J Hematol. 2024 Nov;120(5):621-630. doi: 10.1007/s12185-024-03834-9. Epub 2024 Aug 23.
